New combo pill shows promise for HIV patients fighting TB

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults ≥ 18 years of age with Karnofsky score ≥ 70 * Confirmed rifampicin-susceptible tuberculosis and/or * On first-line rifampicin-based tuberculosis treatment (not \> 8 weeks at the time of enrolment) * Documented HIV-1 infection, ART-naïve OR ART non-naïve (patients to have no exposure to ART medication at least ≥ 3 months at the time of enrollment) * Estimated glomerular filtration rate (eGFR) ≥ 60 mL/min/1.73m2 * Alanine aminotransferase (ALT) ≤3 times the upper limit of normal (ULN) * Total bilirubin ≤2.5 times ULN * Creatinine ≤2 times ULN * Hemoglobin ≥ 7.0 g/dL (6.5 g/dL for females) * Platelet count ≥ 50,000/mm3 * Absolute Neutrophil Count (ANC) ≥650/mm3 * Able and willing to provide written informed consent * Female patients agree to use both a barrier and a non-barrier form of contraception during the study, starting at least 14 days prior to enrolment Exclusion Criteria: * Pregnancy or breastfeeding (or planned pregnancy within 12 months of study entry) * Prior use of antiretroviral drugs for pre-exposure prophylaxis (PrEP) or post-exposure prophylaxis (PEP) \< 3 months at the time of enrolment * Hepatitis B surface antigen positive OR Hepatitis B virus (HBV) infection OR active systemic infections (other than HIV-1 infection) requiring systemic antibiotic or antifungal therapy current or within 30 days prior to baseline that could, in the opinion of the investigator, interfere with study procedures or assessment of study outcomes * Participants with a CD4+ cell count of \< 50 cells/ μl * Any verified Grade 4 laboratory abnormality, with the exception of, Grade 4 triglycerides. A single repeat test is allowed during the Screening period to verify a result * Patients on metformin (\> 500mg, 12hourly) * Patients with an uncontrolled psychiatric co-morbidity. Patients who, in the investigator's judgment, pose a significant suicidality risk. Recent history of suicidal behavior and/or suicidal ideation may be considered as evidence of serious suicide risk * Other condition or circumstance deemed by clinician/investigators to be detrimental to patient safety or study conduct * Unwilling to be part of the main pharmacokinetic (PK) study and have PK blood draws done (NB there is a semi-intensive PK substudy which is optional)